Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Biopharma Contract Manufacturing Market, 2019-2030 - In-Depth Analysis, Capabilities of a Diverse Set of Biopharmaceutical CMOs and CDMOs

      Research and Markets Logo

      News provided by

      Research and Markets

      Jun 24, 2019, 09:00 ET

      Share this article

      Share this article


      DUBLIN, June 24, 2019 /PRNewswire/ -- The "Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.

      The Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 - 2030 report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs.

      Amongst other elements, the report includes:

      • A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.
      • Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.
      • A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody-drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
      • A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
      • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
      • A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug/therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
      • An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.
      • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.
      • An analysis of the recent trends within the biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.
      • A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical/clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).
      • An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.
      • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
      • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.
      • One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as the growth of the overall biopharmaceutical market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced business operations (active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs)), [B] types of expression systems (mammalian, microbial and others), [C] size of the company (small-sized, mid-sized and large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy and Spain), Asia (China and India) and rest of the world (Australia)). To account for the uncertainties associated with the manufacturing of biopharmaceuticals and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

      Key Topics Covered:

      1. Preface
      1.1. Scope of the Report
      1.2. Research Methodology
      1.3. Chapter Outlines

      2. Executive Summary

      3. Introduction
      3.1. Context and Background
      3.2. An Overview of Biopharmaceuticals
      3.3. Biopharmaceutical Manufacturing
      3.3.1. Types of Expression Systems
      3.3.1.1. Bacterial Expression Systems
      3.3.1.2. Yeast Expression Systems
      3.3.1.3. Fungal Expression Systems
      3.3.1.4. Insect Expression Systems
      3.3.1.5. Plant Expression Systems
      3.3.1.6. Mammalian Expression Systems
      3.3.2. Processing Steps
      3.3.2.1. Upstream Processing
      3.3.2.2. Downstream Processing
      3.4. An Overview of Contract Manufacturing
      3.5. Need for Outsourcing in the Biopharmaceutical Industry
      3.6. Commonly Outsourced Operations in the Biopharmaceutical Industry
      3.7. Basic Guidelines for Selecting a CMO Partner
      3.8. Advantages of Outsourcing Manufacturing Services
      3.9. Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing
      3.10. Future Perspectives

      4. Competitive Landscape
      4.1. Chapter Overview
      4.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
      4.2.1. Analysis by Year of Establishment
      4.2.2. Analysis by Size of Employee Base
      4.2.3. Analysis by Location of Headquarters
      4.2.4. Analysis by Location of Manufacturing Facilities
      4.2.5. Analysis by Type of Biologics Manufactured
      4.2.6. Analysis by Scale of Operation
      4.2.7. Analysis by Expression Systems
      4.2.8. Analysis by Type of Bioreactor and Mode of Operation
      4.2.9. Analysis by Biomanufacturing Capacity
      4.2.10. Analysis by Packaging Form

      5. Biopharmaceutical Contract Manufacturing In North America
      5.1. Chapter Overview
      5.2. Biopharmaceutical Outsourcing in the US: Regulatory Scenario
      5.3. Leading Biopharma CMOs in North America
      5.3.1. AMRI (OsoBio)
      5.3.2. Baxter BioPharma Solutions
      5.3.3. Catalent Biologics (Catalent Pharma Solutions)
      5.3.4. Cytovance Biologics
      5.3.5. Patheon
      5.3.6. Piramal Pharma Solutions

      6. Biopharmaceutical Contract Manufacturing In Europe
      6.1. Chapter Overview
      6.2. Biopharmaceutical Outsourcing in Europe: Regulatory Scenario
      6.3. Leading Biopharmaceutical CMOs in Europe
      6.3.1. 3P Biopharmaceuticals
      6.3.2. Boehringer Ingelheim BioXcellence
      6.3.3. Celonic
      6.3.4. FUJIFILM Diosynth Biotechnologies
      6.3.5. LFB Group
      6.3.6. Lonza
      6.3.7. Menarini Biotech
      6.3.8. Novasep
      6.3.9. Rentschler BioPharma

      7. Biopharmaceutical Contract Manufacturing In Asia Pacific And The Rest Of The World
      7.1. Chapter Overview
      7.2. Biopharmaceutical Contract Manufacturing in China
      7.2.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario
      7.3. Biopharmaceutical CMOs in China
      7.3.1. AutekBio
      7.3.2. WuXi AppTec (WuXi Biologics)
      7.4. Biopharmaceutical Contract Manufacturing in India
      7.4.1. Biopharmaceutical Outsourcing in India: Regulatory Scenario
      7.5. Biopharmaceutical CMOs in India
      7.5.1. Intas Pharmaceuticals
      7.5.2. Kemwell Biopharma
      7.5.4. Shasun Pharmaceuticals
      7.5.5. Syngene
      7.6. Biopharmaceutical Contract Manufacturing in Japan
      7.6.1. Biopharmaceutical Outsourcing in Japan: Regulatory Scenario
      7.7. Biopharmaceutical CMOs in Japan
      7.7.1. Asahi Glass
      7.8. Biopharmaceutical Contract Manufacturing in South Korea
      7.8.1. Biopharmaceutical Outsourcing in South Korea: Regulatory Scenario
      7.9. Biopharmaceutical CMOs in South Korea
      7.9.1. DM Bio
      7.9.2. Samsung BioLogics
      7.10. Biopharmaceutical Contract Manufacturing in Australia
      7.10.1. Biopharmaceutical Outsourcing in Australia: Regulatory Scenario
      7.11. Biopharmaceutical CMOs in Australia
      7.11.1. Cell Therapies
      7.11.2. Luina Bio

      8. Niche Biopharmaceutical Sectors
      8.1. Chapter Overview
      8.2. Antibody Drug Conjugates
      8.2.1. Introduction
      8.2.1.1. Manufacturing Process
      8.2.1.2. Key Technologies and Technology Providers
      8.2.2. Pipeline Analysis
      8.2.2.1. ADC Pipeline: Marketed and Clinical Molecules
      8.2.2.2. ADC Pipeline: Preclinical and Discovery Stage Molecules
      8.2.2.3. ADC Manufacturing: Key Challenges
      8.3. Bispecific Antibodies
      8.3.1. Introduction
      8.3.1.1.The Bispecific Advantage
      8.3.2. Pipeline Analysis
      8.3.3. Bispecific Antibody Technology Providers
      8.3.4. Contract Manufacturing Scenario
      8.4. Cell Therapies
      8.4.1. Introduction
      8.4.2. Current Market Landscape
      8.4.3. Cell Therapy Manufacturing
      8.4.4. Cell Therapy Manufacturing Models
      8.4.4.1. Centralized Manufacturing Model
      8.4.4.2. Decentralized Manufacturing Model
      8.4.5. Cell Therapy Manufacturing: Key Challenges and Growth Drivers
      8.4.6. Important Factors for Cell Therapy Manufacturing
      8.4.7. Contract Manufacturing Scenario
      8.4.7.1. Contract Manufacturing Market Landscape
      8.4.7.2. Analysis by Type of Cells Manufactured
      8.4.7.3. Analysis by Scale of Operation
      8.5. Gene Therapy
      8.5.1. Introduction
      8.5.2. Gene Therapy: Pipeline Analysis
      8.5.2.1. Analysis by Phase of Development
      8.5.2.2. Analysis by Type of Vector
      8.5.2.3. Analysis by Therapeutic Area
      8.5.3. Contract Manufacturing Market Landscape
      8.5.3.1. Analysis by Location
      8.5.3.2. Analysis by Type of Viral Vector
      8.5.3.3. Analysis by Scale of Production
      8.6. Plasmid DNA
      8.6.1. Introduction
      8.6.2. Contract Manufacturing Market Landscape
      8.6.3. Analysis by Location of Manufacturing Facility
      8.6.4. Analysis by Scale of Production

      9. Case Study: Outsourcing Of Biosimilars
      9.1. Chapter Overview
      9.2. Biosimilars: An Introduction
      9.3. Biosimilars: Development Stages
      9.4. Regulatory Requirements for Licensing Biosimilars
      9.5. Need for Outsourcing Biosimilar Development and Manufacturing
      9.6. Impact of Biosimilars on the Global Contract Manufacturing Market
      9.6.1. Region-wise Distribution of Biosimilar Development / Manufacturing Activity
      9.7. Challenges Associated with Outsourcing Biosimilars

      10. Case Study: Comparison Of Small Molecule Andlarge Molecule Drugs/Therapies
      10.1. Chapter Overview
      10.2. Small Molecule and Large Molecule Drugs / Therapies
      10.2.1. Comparison of General Characteristics
      10.2.2. Comparison of Key Specifications
      10.2.3. Comparison of Manufacturing Processes
      10.2.4. Comparison of Key Manufacturing Challenges

      11. Case Study On In-House Manufacturing
      11.1. Chapter Overview
      11.2. In-House Manufacturing
      11.2.1. Benefits Associated with In-House Manufacturing
      11.2.2. Risks Associated with In-House Manufacturing
      11.3. Outsourcing in the Biomanufacturing Industry
      11.3.1. Types of Outsourcing Partners
      11.4. Manufacturing Approaches Used for Approved Biologics (2016-2018)
      11.4.1. Approved Biologics: Analysis by Size of Developer and Type of Manufacturing Approach
      11.4.2. Approved Biologics: Analysis by Size of Developer and Type of Biologic
      11.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

      12. Collaborations
      12.1. Chapter Overview
      12.2. Partnership Models
      12.3. Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations
      12.3.1. Analysis by Year of Partnership
      12.3.2. Analysis by Type of Partnership
      12.3.2.1. Year-Wise Trend of Product-based Agreements
      12.3.2.2. Year-Wise Trend of Process-based Agreements
      12.3.2.3. Year-Wise Trend of Licensing Agreements
      12.3.2.4. Year-Wise Trend of Co-service Agreements / Ventures
      12.3.2.5. Year-Wise Trend of R&D Agreements
      12.3.2.6. Year-Wise Trend of Out-sourcing Services Agreements
      12.3.3. Analysis by Focus Area
      12.3.4. Analysis by Type of Biologic
      12.3.4.1. Analysis by Type of Biologic and Type of Partnership Model
      12.3.4.2. Analysis of Cell Therapy-related Deals by Year and Type of Partnership Model
      12.3.4.3. Analysis of Monoclonal Antibody-related Deals Year and Type of Partnership Model
      12.3.4.4. Analysis of Vaccine-related Deals by Year and Type of Partnership Model
      12.3.4.5. Analysis of Protein-related Deals by Year and Type of Partnership Model
      12.3.4.6. Analysis of Antibody Drug Conjugate-related Deals by Year and Type of Partnership Model
      12.3.4.7. Analysis of Vector-related Deals by Year and Type of Partnership Model
      12.3.4.8. Analysis of Gene Therapy-related Deals by Year and Type of Partnership Model
      12.3.4.9. Analysis of Biosimilar-related Deals by Year and Type of Partnership Model
      12.3.4.10. Analysis of Other Biologic-related Deals by Type of Partnership Model
      12.3.4.11. Analysis by Type of Biologic and Geography
      12.3.5. Analysis by Therapeutic Area
      12.3.6. Analysis of Most Active Players by Number of Partnerships
      12.3.7. Regional Analysis
      12.3.7.1. Intercontinental and Intracontinental Agreements
      12.4. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions
      12.4.1. Cumulative Year-wise Trend
      12.4.2. Analysis by Type of Acquisition
      12.4.3. Regional Analysis
      12.4.3.1. Continent-wise Distribution
      12.4.3.2. Country-wise Distribution
      12.4.3.3. Intercontinental and Intracontinental Deals
      12.4.4. Analysis of Most Active Acquirers by Number of Acquisitions
      12.4.5. Analysis by Key Value Drivers
      12.4.5.1. Analysis by Key Value Drivers and Year of Acquisition
      12.4.6. Analysis by Type of Biologic
      12.5.6.1. Analysis by Type of Biologic and Key Value Drivers
      12.4.7 Key Acquisitions: Deal Multiples

      13. Recent Developments
      13.1. Chapter Overview
      13.2. Biopharmaceutical Contract Manufacturing Market: Facility Expansions
      13.2.1. Cumulative Year-wise Distribution
      13.2.2. Analysis by Purpose of Facility Expansion
      13.2.3. Analysis by Type of Biologic
      13.2.4. Analysis by Location of Facility
      13.2.5. Regional Analysis
      13.2.6. Analysis by Region and Purpose
      13.3. Biopharmaceutical Contract Manufacturing Market: Funding Instances
      13.4. Technological Advancements
      13.4.1. Single Use Technology
      13.4.2. Process Analytical Technology
      13.4.3. Continuous Processing
      13.4.4. Quality by Design in Bio-processing

      14. Capacity Analysis
      14.1. Chapter Overview
      14.2. Assumptions and Methodology
      14.3. Biopharmaceutical Contract Manufacturers: Global Production Capacity
      14.3.1. Analysis by Region
      14.3.2. Analysis by Expression Systems
      14.3.3. Analysis by Scale of Operation
      14.4. ADC Contract Manufacturers: Global Production Capacity
      14.5. Cell Therapy Manufacturers: Production Capacity
      14.6. Vector Manufacturers: Production Capacity
      14.7. Concluding Remarks

      15. Demand Analysis
      15.1. Chapter Overview
      15.2. Key Assumptions and Methodology
      15.3. Biopharmaceutical Contract Manufacturing Market: Overall Annual Demand
      15.3.1. Analysis by Therapeutic Area
      15.4. ADCs: Overall Annual Demand
      15.4.1. ADCs: Demand and Supply Analysis

      16. Market Forecast
      16.1. Chapter Overview
      16.2. Forecast Methodology and Key Assumptions
      16.3. Overall Biopharmaceutical Contract Manufacturing Market, 2019-2030
      16.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2019-2030
      16.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2019-2030
      16.4. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Expression Systems Used
      16.5. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation
      16.6. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Size of Manufacturers
      16.7. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Geography

      17. SWOT Analysis
      17.1 Chapter Overview
      17.2. Strengths
      17.3. Weaknesses
      17.4. Opportunities
      17.5. Threats
      17.6. Comparison of Swot Factors
      17.7. Concluding Remarks

      18. Future Of The Biopharmaceutical CMO Market
      18.1. Chapter Overview
      18.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
      18.3. Shift from One-time Contracts to Strategic Partnerships
      18.4. Integration / Adoption of New and Innovative Technologies
      18.4.1. Single use Bioreactors
      18.4.2. Novel Bioprocess Techniques
      18.4.3. Bioprocess Automation
      18.5. Focus on Niche Therapeutic Areas
      18.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
      18.7. Capability and Expertise Expansions by CMOs to become One Stop Shops
      18.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
      18.9. Increase in Financial Inflow and Outsourcing Budgets
      18.10. The Need for Humanized Products to Drive the Growth of Mammalian Expression Technologies
      18.11. Challenges Faced by both Sponsors and Service Providers
      18.11.1. Concerns related to Single Use Systems
      18.11.2. Issues Related to Capacity Fluctuations
      18.12. Concluding Remarks

      19. Survey Analysis
      19.1. Chapter Overview
      19.1.1. Overview of Respondents
      19.1.2. Designation of Respondents
      19.2. Biologics Manufacturing Expertise
      19.3. Scale of Manufacturing
      19.4. Location of Production Facilities
      19.5. Types of Expression Systems Used
      19.6. Types of Bioreactors
      19.7. Modes of Operation of Bioreactors

      20. Interview Transcripts
      20.1. Chapter Overview
      20.2. Astrid Brammer, Senior Manager Business Development, Richter-Helm
      20.3. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
      20.4. Christian Bailly, Director of CDMO, Pierre Fabre
      20.5. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
      20.6. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
      20.7. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
      20.8. Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
      20.9. Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
      20.10. Kevin Daley, Director Pharmaceuticals, Novasep
      20.11. Mark Wright, Site Head, Grangemouth, Piramal Healthcare
      20.12. Nicolas Grandchamp, R&D Leader, GEG Tech
      20.13. Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
      20.14. Sebastian Schuck, Head of Business Development, Wacker Biotech
      20.15. Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
      20.16. Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
      20.17. Tim Oldham, Chief Executive Officer, Cell Therapies

      21. Appendix 1: List Of Non-Industry Players

      22. Appendix 2: Tabulated Data

      23. Appendix 3: List Of Companies And Organizations

      For more information about this report visit https://www.researchandmarkets.com/r/xeyvij

      Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

      Media Contact:

      Research and Markets
      Laura Wood, Senior Manager
      [email protected]

      For E.S.T Office Hours Call +1-917-300-0470
      For U.S./CAN Toll Free Call +1-800-526-8630
      For GMT Office Hours Call +353-1-416-8900

      U.S. Fax: 646-607-1907
      Fax (outside U.S.): +353-1-481-1716

      SOURCE Research and Markets

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.